Yuping Shen

Innovent Biologics, Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

45

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

An Anti-CTLA-4 Antibody Ibi310 Alone or in Combination with Sintilimab in Patients with Advanced Melanoma or Urothelial Carcinoma: A Phase Ia/Ib Study

Number of pages: 27 Posted: 30 Nov 2023
Beijing Cancer Hospital, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University, Innovent Biologics, Inc., Innovent Biologics, Inc., Innovent Biologics, Inc., Peking University - Key Laboratory of Carcinogenesis and Translational Research and Peking University - Key Laboratory of Carcinogenesis and Translational Research
Downloads 45 (895,370)

Abstract:

Loading...

CTLA-4, IBI310, Combination immunotherapy, Melanoma, Urothelial carcinoma